REDUCTION IN WORKFORCE |
12 Months Ended |
|---|---|
Jun. 30, 2026 | |
| REDUCTION IN WORKFORCE | |
| REDUCTION IN WORKFORCE | NOTE 16 — REDUCTION IN WORKFORCE On December 11, 2025, the Company announced that its Phase 3 sunRIZE clinical trial did not meet its primary endpoint or key secondary endpoint. Management approved a reduction in workforce of 29 employees on December 15, 2025 to reduce overall operating expenses and preserve capital to support the Company’s Phase 3 upLIFT clinical trial and plan for future interactions with the FDA to discuss the full sunRIZE dataset and next steps for the program. The Company incurred $1.5 million of severance expenses in December 2025, consisting of $0.9 million of research and development expense and $0.6 million of general and administrative expense. Total severance benefits of $1.5 million were paid in full to the affected employees in January 2026 and no obligations related to the severance benefits remain as of June 30, 2026. |